Breaking News Instant updates and real-time market news.

2022-07-06 10:04:56 SWGAY Swatch Group $11.51 / -0.33 (-2.79%) 10:04 07/06/22 07/06 10:04 07/06/22 10:04	Swatch Group price target lowered to CHF 360 from CHF 385 at Barclays Barclays analyst Carole Madjo lowered the firm's price target on Swatch Group to CHF 360 from CHF 385 and keeps an Overweight rating on the shares.

2022-07-06 10:04:56

SWGAY

Swatch Group

$11.51 / -0.33 (-2.79%)

10:04

07/06/22

07/06

10:04

07/06/22

10:04

Swatch Group price target lowered to CHF 360 from CHF 385 at Barclays

Barclays analyst Carole Madjo lowered the firm's price target on Swatch Group to CHF 360 from CHF 385 and keeps an Overweight rating on the shares.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks	Rapid Micro Biosystems announces review of strategic alternatives » 07:07 08/12/22 08/12 07:07 08/12/22 07:07 RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) Rapid Micro Biosystems… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 07:06 Today Rapid Micro Biosystems rejects non-binding proposal from Kennedy Lewis 07:05 Today Rapid Micro Biosystems CCO Andy Keys departs 07:05 Today Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction 06/30/22 Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 10/14/21 Cowen Rapid Micro Biosystems coverage transferred at Cowen RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 07:03 Today Rapid Micro Biosystems lowers FY22 revenue view to at least $17M 07:02 Today Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year 05/10/22 Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M 05/10/22 Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c) 08:30 Today Rapid Micro Biosystems - RPID
Recommendations	Marriott Vacations price target lowered to $202 from $205 at Truist » 07:07 08/12/22 08/12 07:07 08/12/22 07:07 VAC Marriott Vacations $146.63 / +1.64 (+1.13%) Truist analyst Patrick… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings VAC Marriott Vacations $146.63 / +1.64 (+1.13%) 08/01/22 Marriott Vacations raises share repurchase authorization by $500M 06/16/22 Marriott Vacations raises 2022 contract sales guidance by $100M 06/09/22 Marriott Vacations CEO Stephen Weisz to retire, John Geller, Jr to succeed 02/23/22 Marriott Vacations sees FY22 contract sales up 13% vs. 2019 VAC Marriott Vacations $146.63 / +1.64 (+1.13%) 08/10/22 Barclays Marriott Vacations price target raised to $165 from $136 at Barclays 08/10/22 Deutsche Bank Marriott Vacations price target raised to $192 from $188 at Deutsche Bank 06/28/22 Barclays Barclays says shift in preferences to cushion Gaming, Cruises, Timeshare names 06/28/22 Barclays Marriott Vacations initiated with an Overweight at Barclays VAC Marriott Vacations $146.63 / +1.64 (+1.13%) 08/08/22 Marriott Vacations sees FY22 adjusted EPS $9.47-$10.35, consensus $9.49 08/08/22 Marriott Vacations reports Q2 adjusted EPS $2.87, consensus $2.27 05/05/22 Marriott Vacations sees FY22 adjusted EPS $9.13-$10.09, consensus $9.22 05/05/22 Marriott Vacations reports Q1 adjusted EPS $1.70, consensus $1.53
Recommendations	Travel + Leisure price target lowered to $72 from $78 at Truist » 07:07 08/12/22 08/12 07:07 08/12/22 07:07 TNL Travel + Leisure $45.78 / +0.795 (+1.77%) Truist analyst C. Patrick… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings TNL Travel + Leisure $45.78 / +0.795 (+1.77%) 04/28/22 Travel + Leisure board approves $500M increase to share repurchase plan 03/02/22 Travel + Leisure increases quarterly cash dividend 5c to 40c per share TNL Travel + Leisure $45.78 / +0.795 (+1.77%) 08/01/22 Deutsche Bank Travel + Leisure price target lowered to $69 from $76 at Deutsche Bank 07/28/22 Stifel Travel + Leisure price target lowered to $61 from $76 at Stifel 06/28/22 Barclays Travel + Leisure initiated with an Equal Weight at Barclays 04/29/22 Jefferies Travel + Leisure upgraded to Buy at Jefferies after positive headline results TNL Travel + Leisure $45.78 / +0.795 (+1.77%) 07/28/22 Travel + Leisure sees FY22 adjusted EBITDA $860M-$880M 07/28/22 Travel + Leisure sees Q3 adjusted EBITDA $230M-$240M 07/28/22 Travel + Leisure reports Q2 adjusted EPS $1.27, consensus $1.19 04/28/22 Travel + Leisure sees FY22 adjusted EBITDA $855M-$875M
Recommendations	Hilton Grand Vacations price target lowered to $63 from $64 at Truist » 07:07 08/12/22 08/12 07:07 08/12/22 07:07 HGV Hilton Grand Vacations $43.49 / -0.17 (-0.39%) Truist analyst C. Patrick… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events HGV Hilton Grand Vacations $43.49 / -0.17 (-0.39%) 05/09/22 Hilton Grand Vacations sees 2022 Deferral Adjusted EBITDA $600M-$990M 05/09/22 Hilton Grand Vacations board approves $500M share repurchase program 05/09/22 Hilton Grand Vacations expects cost synergies of $150M from Diamond transaction HGV Hilton Grand Vacations $43.49 / -0.17 (-0.39%) 06/28/22 Barclays Barclays says shift in preferences to cushion Gaming, Cruises, Timeshare names 06/28/22 Barclays Hilton Grand Vacations initiated with an Overweight at Barclays 03/08/22 Truist Hilton Grand Vacations price target raised to $63 from $60 at Truist 12/06/21 Truist Hilton Grand Vacations price target raised to $60 from $54 at Truist HGV Hilton Grand Vacations $43.49 / -0.17 (-0.39%) 08/09/22 Hilton Grand Vacations backs FY22 adjusted EBITDA view $960M-$990M 08/09/22 Hilton Grand Vacations reports Q2 EPS with-items 60c, consensus 88c 05/09/22 Hilton Grand Vacations reports Q1 EPS 42c, consensus 64c 03/01/22 Hilton Grand Vacations reports Q4 EPS 62c, one estimate 88c 09/22/22 Hilton Grand Vacations - HGV
Earnings	Applied Therapeutics reports Q2 EPS (96c), consensus (78c) » 07:06 08/12/22 08/12 07:06 08/12/22 07:06 APLT Applied Therapeutics $1.31 / +0.09 (+7.38%) Cash and cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly APLT Applied Therapeutics $1.31 / +0.09 (+7.38%) 06/03/22 Applied receives orphan medicinal product designation from EMA for AT-007 02/28/22 Applied Therapeutics supports annual Rare Disease Day APLT Applied Therapeutics $1.31 / +0.09 (+7.38%) 04/13/22 Truist Applied Therapeutics price target lowered to $6 from $85 at Truist 03/21/22 Barclays Applied Therapeutics price target lowered to $2.50 from $7 at Barclays 01/05/22 Citi Applied Therapeutics price target lowered to $30 from $38 at Citi 01/04/22 Goldman Sachs Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs APLT Applied Therapeutics $1.31 / +0.09 (+7.38%) 05/12/22 Applied Therapeutics reports Q1 EPS (88c), consensus (83c) 03/10/22 Applied Therapeutics reports FY21 EPS ($4.12), consensus ($4.38) 23 Jun APLT Applied Therapeutics $1.31 / +0.09 (+7.38%) 06/22/22 Fly Intel: After-Hours Movers
Recommendations	Bluegreen Vacations price target lowered to $56 from $57 at Truist » 07:06 08/12/22 08/12 07:06 08/12/22 07:06 BVH Bluegreen Vacations $23.67 / +0.01 (+0.04%) Truist analyst C. Patrick… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings BVH Bluegreen Vacations $23.67 / +0.01 (+0.04%) 03/03/22 Bluegreen Vacations authorizes additional $50M share repurchase program BVH Bluegreen Vacations $23.67 / +0.01 (+0.04%) 03/08/22 Truist Bluegreen Vacations price target raised to $56 from $44 at Truist 11/16/21 Truist Bluegreen Vacations price target raised to $44 from $41 at Truist 11/05/21 B. Riley Bluegreen Vacations price target raised to $59 from $42.50 at B. Riley 09/29/21 Truist Bluegreen Vacations Holding assumed with a Buy at Truist BVH Bluegreen Vacations $23.67 / +0.01 (+0.04%) 03/03/22 Bluegreen Vacations reports Q4 cont-op EPS 59c, consensus 62c
Hot Stocks	Rapid Micro Biosystems rejects non-binding proposal from Kennedy Lewis » 07:06 08/12/22 08/12 07:06 08/12/22 07:06 RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) In addition, the Company… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 07:05 Today Rapid Micro Biosystems CCO Andy Keys departs 07:05 Today Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction 06/30/22 Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis 06/30/22 Kennedy Lewis proposes to buy Rapid Micro Biosystems for $5.00 per share in cash RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 10/14/21 Cowen Rapid Micro Biosystems coverage transferred at Cowen RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 07:03 Today Rapid Micro Biosystems lowers FY22 revenue view to at least $17M 07:02 Today Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year 05/10/22 Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M 05/10/22 Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c) 08:30 Today Rapid Micro Biosystems - RPID
Downgrade	TIS Inc. downgraded to Neutral from Buy at Citi » 07:06 08/12/22 08/12 07:06 08/12/22 07:06 TISNF TIS Inc. / + Citi analyst Mitsunobu… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research TISNF TIS Inc. / + 05/26/22 Jefferies TIS Inc. downgraded to Hold from Buy at Jefferies 12/14/21 Daiwa TIS Inc. upgraded to Outperform from Neutral at Daiwa 10/01/21 Credit Suisse TIS Inc. downgraded to Neutral from Outperform at Credit Suisse 09/17/21 Daiwa TIS Inc. downgraded to Neutral from Outperform at Daiwa
Recommendations	System1 price target lowered to $13 from $15 at Benchmark » 07:06 08/12/22 08/12 07:06 08/12/22 07:06 SST System1 $8.69 / +0.045 (+0.52%) Benchmark analyst Daniel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options SST System1 $8.69 / +0.045 (+0.52%) 06/07/22 System1 set to join Russell 2000, Russell 3000 Indexes 05/13/22 Starboard takes stake in Humana, exits System1 04/19/22 System1 falls -33.8% 04/19/22 System1 falls -28.6% SST System1 $8.69 / +0.045 (+0.52%) 07/11/22 BofA BofA starts System1 at Buy with $12 price target 07/11/22 BofA System1 initiated with a Buy at BofA 04/26/22 Evercore ISI System1 initiated with an In Line at Evercore ISI 04/06/22 DA Davidson System1 price target raised to $26 from $23 at DA Davidson SST System1 $8.69 / +0.045 (+0.52%) 08/11/22 System1 sees FY22 revenue $900M-$930M, consensus $997.34M 08/11/22 System1 reports Q2 revenue $220M, consensus $218.82M 04/04/22 System1 sees FY22 revenue $1B 04/04/22 System1 reports Q4 revenue $238.9M vs. $160.9M last year SST System1 $8.69 / +0.045 (+0.52%) 08/11/22 Fly Intel: After-Hours Movers 05/20/22 Proven algorithm says sell these stocks now 04/19/22 What You Missed On Wall Street This Morning 04/18/22 Fly Intel: After-Hours Movers 09/08/22 Consumer/Media/Entertainment Conference SST System1 $8.69 / +0.045 (+0.52%) 08/11/22 System1 options imply 10.1% move in share price post-earnings 07/29/22 Largest borrow rate increases among liquid names 07/22/22 Largest borrow rate increases among liquid names 07/21/22 Largest borrow rate increases among liquid names
Hot Stocks	Iterum Therapeutics expects cash to fund operations into 2024 » 07:05 08/12/22 08/12 07:05 08/12/22 07:05 ITRM Iterum Therapeutics $0.25 / +0.0007 (+0.28%) Cash, cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings ITRM Iterum Therapeutics $0.25 / +0.0007 (+0.28%) 07/11/22 Iterum announces SPA agreement with FDA on Phase 3 trial of oral sulopenem 05/13/22 Iterum Therapeutics sees cash, equivalents funding operations into 2024 05/11/22 Iterum reaches 'general alignment' with FDA on aspects of Phase 3 trial design 03/28/22 Iterum Therapeutics sees cash, cash equivalents funding operations into 2024 ITRM Iterum Therapeutics $0.25 / +0.0007 (+0.28%) 07:05 Today Iterum Therapeutics reports Q2 adjusted EPS (3c) vs (4c) last year 05/13/22 Iterum Therapeutics reports Q1 adjusted EPS (3c) vs. (5c) last year 03/28/22 Iterum Therapeutics reports Q4 adjusted EPS (2c) vs. (11c) last year

Earnings	Iterum Therapeutics reports Q2 adjusted EPS (3c) vs (4c) last year » 07:05 08/12/22 08/12 07:05 08/12/22 07:05 ITRM Iterum Therapeutics $0.25 / +0.0007 (+0.28%) "We are excited to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings ITRM Iterum Therapeutics $0.25 / +0.0007 (+0.28%) 07/11/22 Iterum announces SPA agreement with FDA on Phase 3 trial of oral sulopenem 05/13/22 Iterum Therapeutics sees cash, equivalents funding operations into 2024 05/11/22 Iterum reaches 'general alignment' with FDA on aspects of Phase 3 trial design 03/28/22 Iterum Therapeutics sees cash, cash equivalents funding operations into 2024 ITRM Iterum Therapeutics $0.25 / +0.0007 (+0.28%) 05/13/22 Iterum Therapeutics reports Q1 adjusted EPS (3c) vs. (5c) last year 03/28/22 Iterum Therapeutics reports Q4 adjusted EPS (2c) vs. (11c) last year
Earnings	Casi Pharmaceuticals reports Q2 EPS (56c), consensus (64c) » 07:05 08/12/22 08/12 07:05 08/12/22 07:05 CASI Casi Pharmaceuticals $3.91 / +0.91 (+30.33%) Reports Q2 revenue $8.6M,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CASI Casi Pharmaceuticals $3.91 / +0.91 (+30.33%) 07/08/22 Casi announces Precision Autoimmune completed first-round financing of $21M 05/26/22 Casi Pharmaceuticals announces 1-for-10 reverse stock split 05/24/22 Casi signs sublicense agreement with Beijing Tianshi Tongda for anti-CD38 04/01/22 Casi Pharmaceuticals issues statement on status under HFCAA CASI Casi Pharmaceuticals $3.91 / +0.91 (+30.33%) 06/03/22 BTIG Casi Pharmaceuticals price target adjusted to $21 at BTIG after 1 for 10 split 05/26/22 Oppenheimer Casi Pharmaceuticals should benefit from Shanghai's reopening, says Oppenheimer 05/13/22 H.C. Wainwright Casi Pharmaceuticals price target lowered to $3 from $4 at H.C. Wainwright CASI Casi Pharmaceuticals $3.91 / +0.91 (+30.33%) 05/12/22 Casi Pharmaceuticals reports Q1 EPS (6c), consensus (9c) 02/16/22 Casi Pharmaceuticals sees FY22 revenue growth 30%, consensus $39.75M 02/16/22 Casi Pharmaceuticals sees Q4 revenue $9.12M, consensus $8.5M 08:00 Today Casi Pharmaceuticals - CASI
Hot Stocks	Rapid Micro Biosystems CCO Andy Keys departs » 07:05 08/12/22 08/12 07:05 08/12/22 07:05 RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) In connection with the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 07:05 Today Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction 06/30/22 Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis 06/30/22 Kennedy Lewis proposes to buy Rapid Micro Biosystems for $5.00 per share in cash RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 10/14/21 Cowen Rapid Micro Biosystems coverage transferred at Cowen RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 07:03 Today Rapid Micro Biosystems lowers FY22 revenue view to at least $17M 07:02 Today Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year 05/10/22 Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M 05/10/22 Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c) 08:30 Today Rapid Micro Biosystems - RPID
Earnings	Fennec reports Q2 EPS (19c), consensus (14c) » 07:05 08/12/22 08/12 07:05 08/12/22 07:05 FENC Fennec $6.99 / +0.07 (+1.01%) Cash and cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events FENC Fennec $6.99 / +0.07 (+1.01%) 08/01/22 Fennec announces up to $45M investment from Petrichor 04/27/22 Fennec announces FDA approval of NDA resubmission for PEDMARK 03/24/22 Fennec resubmits NDA to FDA for Pedmark 02/28/22 Fennec expects cash to fund activities for 2022 FENC Fennec $6.99 / +0.07 (+1.01%) 08/08/22 Craig-Hallum Fennec assumed with a Buy at Craig-Hallum 12/01/21 Maxim Fennec price target lowered to $10 from $12 at Maxim 11/30/21 Craig-Hallum Fennec price target lowered to $14 from $19 at Craig-Hallum FENC Fennec $6.99 / +0.07 (+1.01%) 02/28/22 Fennec reports Q4 EPS (18c), consensus 75c 09/23/22 PDUFA Date for Pedmark
Hot Stocks	Rapid Micro Biosystems announces restructuring plan with 20% workforce reduction » 07:05 08/12/22 08/12 07:05 08/12/22 07:05 RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) The Company is… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 06/30/22 Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis 06/30/22 Kennedy Lewis proposes to buy Rapid Micro Biosystems for $5.00 per share in cash RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 10/14/21 Cowen Rapid Micro Biosystems coverage transferred at Cowen RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 07:03 Today Rapid Micro Biosystems lowers FY22 revenue view to at least $17M 07:02 Today Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year 05/10/22 Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M 05/10/22 Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c) 08:30 Today Rapid Micro Biosystems - RPID
Earnings	Leap Therapeutics reports Q2 EPS (15c), consensus (10c) » 07:04 08/12/22 08/12 07:04 08/12/22 07:04 LPTX Leap Therapeutics $1.32 / +0.15 (+12.82%) Cash and cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate LPTX Leap Therapeutics $1.32 / +0.15 (+12.82%) 07/12/22 Leap Therapeutics and BeiGene begin Part C of the DisTinGuish study 05/26/22 Leap Therapeutics presents initial Phase 1b/2 data of DKN-01 in prostate cancer LPTX Leap Therapeutics $1.32 / +0.15 (+12.82%) 06/06/22 Piper Sandler Piper says Leap's DKN-01 combo showed 'interesting early signal of activity' 05/27/22 Piper Sandler Leap Therapeutics price target lowered to $4 from $6 at Piper Sandler 01/23/22 Piper Sandler Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update 12/30/21 Mizuho Mizuho announces top oncology stock picks for 2022 LPTX Leap Therapeutics $1.32 / +0.15 (+12.82%) 05/13/22 Leap Therapeutics reports Q1 EPS (9c), consensus (10c) 03/11/22 Leap Therapeutics reports Q4 EPS (10c), consensus (11c) 22 Sep
Earnings	Rapid Micro Biosystems lowers FY22 revenue view to at least $17M » 07:03 08/12/22 08/12 07:03 08/12/22 07:03 RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) Consensus $28.01M. The… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 06/30/22 Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis 06/30/22 Kennedy Lewis proposes to buy Rapid Micro Biosystems for $5.00 per share in cash RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 10/14/21 Cowen Rapid Micro Biosystems coverage transferred at Cowen RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 07:02 Today Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year 05/10/22 Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M 05/10/22 Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c) 03/04/22 Rapid Micro Biosystems backs FY22 commercial revenue view $27M-$32M 08:30 Today Rapid Micro Biosystems - RPID
Earnings	Humacyte reports Q2 EPS 35c, consensus (22c) » 07:03 08/12/22 08/12 07:03 08/12/22 07:03 HUMA Humacyte $4.38 / +0.89 (+25.50%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events HUMA Humacyte $4.38 / +0.89 (+25.50%) 07/19/22 Humacyte announces presentation of preclinical data on HAV 07/07/22 Humacyte to host KOL webinar on Human Acellular Vessels 06/29/22 Humacyte announces JAMA Surgery publication on HAV's potential 06/21/22 Humacyte provides update on patients treated with HAV in Ukraine HUMA Humacyte $4.38 / +0.89 (+25.50%) 07/18/22 BTIG Humacyte price target lowered to $10 from $12 at BTIG 05/15/22 Piper Sandler Humacyte downgraded to Underweight from Overweight at Piper Sandler 03/29/22 Piper Sandler Humacyte price target lowered to $10 from $17 at Piper Sandler 10/29/21 Cowen Humacyte initiated with an Outperform at Cowen HUMA Humacyte $4.38 / +0.89 (+25.50%) 05/13/22 Humacyte reports Q1 EPS (19c), consensus (21c) 03/29/22 Humacyte reports Q4 EPS 41c, consensus (20c) HUMA Humacyte $4.38 / +0.89 (+25.50%) 05/16/22 What You Missed On Wall Street On Monday 05/16/22 What You Missed On Wall Street This Morning 08:00 Today Humacyte - HUMA
Earnings	Ocuphire Pharma reports Q2 EPS (25c) vs (52c) last year » 07:03 08/12/22 08/12 07:03 08/12/22 07:03 OCUP Ocuphire Pharma $2.76 / +0.405 (+17.23%) "Ocuphire has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings OCUP Ocuphire Pharma $2.76 / +0.405 (+17.23%) 08/03/22 Ocuphire Pharma extends US patent protection for Nyxol 06/29/22 Ocuphire Pharma granted new US patent for APX3330 06/08/22 Ocuphire Pharma to present interim masked safety data for oral APX3330 05/19/22 Ocuphire Pharma says LYNX-1 Phase 3 trial met primary endpoint OCUP Ocuphire Pharma $2.76 / +0.405 (+17.23%) 05/19/22 Alliance Global Partners Alliance Global Partners says Ocuphire's Nyxol trial run 'remarkable' 11/24/21 H.C. Wainwright Ocuphire Pharma initiated with a Buy at H.C. Wainwright 10/06/21 Spartan Capital Ocuphire Pharma initiated with a Buy at Spartan Capital OCUP Ocuphire Pharma $2.76 / +0.405 (+17.23%) 05/13/22 Ocuphire Pharma reports Q1 EPS (35c), consensus (35c) 03/24/22 Ocuphire Pharma reports Q4 EPS (35c), consensus (29c)
Downgrade	Powszechny Zaklad Ubezpieczen downgraded to Neutral from Buy at Citi » 07:03 08/12/22 08/12 07:03 08/12/22 07:03 PWZYF Powszechny Zaklad Ubezpieczen $7.69 / + (+0.00%) Citi analyst Andrzej… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research PWZYF Powszechny Zaklad Ubezpieczen $7.69 / + (+0.00%) 06/21/22 JPMorgan Powszechny Zaklad Ubezpieczen price target lowered to PLN 46.90 at JPMorgan 05/10/22 JPMorgan PZU price target lowered to PLN 49.25 from PLN 52.75 at JPMorgan 12/14/21 JPMorgan Powszechny Zaklad Ubezpieczen price target raised to PLN 152.75 at JPMorgan

Earnings	Honest Company sees FY22 revenue growth flat, consensus $318.65M » 07:03 08/12/22 08/12 07:03 08/12/22 07:03 HNST Honest Company $3.83 / +0.005 (+0.13%) Revenue outlook reflects… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options HNST Honest Company $3.83 / +0.005 (+0.13%) 07/19/22 Honest Company launches at Walmart to expand U.S. distribution 03/28/22 Honest Company partners with Fast 03/24/22 Honest Company drops 19% to $4.88 after Q4 results miss estimates HNST Honest Company $3.83 / +0.005 (+0.13%) 06/09/22 Loop Capital Loop Capital cuts Honest Company to Hold amid pressure reported in mass retail 06/09/22 Loop Capital Honest Company downgraded to Hold from Buy at Loop Capital 05/16/22 Loop Capital Honest Company price target lowered to $5 from $8 at Loop Capital 03/28/22 Citi Honest Company shares look 'awfully cheap' after selloff, says Citi HNST Honest Company $3.83 / +0.005 (+0.13%) 07:02 Today Honest Company reports Q2 EPS (11c), consensus (8c) 05/13/22 Honest Company still sees 2022 revenue growth view flat vs. 2021 05/13/22 Honest Company reports Q1 EPS (16c), consensus (15c) 03/24/22 Honest Company sees FY22 revenue flat, consensus $366.79M HNST Honest Company $3.83 / +0.005 (+0.13%) 06/09/22 What You Missed On Wall Street On Thursday 06/09/22 What You Missed On Wall Street This Morning 06/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/13/22 What You Missed On Wall Street On Friday 12:00 Today Honest Company - HNST HNST Honest Company $3.83 / +0.005 (+0.13%) 03/24/22 Honest Company options imply 7.1% move in share price post-earnings
Hot Stocks	Broadridge raises annual dividend 13% to $2.90 from $2.56 per share » 07:02 08/12/22 08/12 07:02 08/12/22 07:02 BR Broadridge $169.66 / -0.745 (-0.44%) On August 11,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events BR Broadridge $169.66 / -0.745 (-0.44%) 07/06/22 Broadridge appoints Tyler Derr as CTO BR Broadridge $169.66 / -0.745 (-0.44%) 08/17/21 JPMorgan Broadridge price target raised to $197 from $181 at JPMorgan 08/16/21 DA Davidson Broadridge price target raised to $158 from $152 at DA Davidson 08/13/21 JPMorgan Broadridge assumed with an Overweight at JPMorgan BR Broadridge $169.66 / -0.745 (-0.44%) 07:01 Today Broadridge sees FY23 adjusted EPS growth 7%-11%, consensus $7.06 07:00 Today Broadridge reports Q4 adjusted EPS $2.65, consensus $2.62 05/03/22 Broadridge raises FY22 adjusted EPS growth view to 13%-15% from 11%-15% 05/03/22 Broadridge reports Q3 adjusted EPS $1.93, consensus $1.78 08:30 Today Broadridge - BR
Earnings	Maverix Metals reports Q2 adjusted EPS 3c, consensus 3c » 07:02 08/12/22 08/12 07:02 08/12/22 07:02 MMX Maverix Metals $4.06 / -0.07 (-1.69%) Reports Q2 revenue $14.2M… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings MMX Maverix Metals $4.06 / -0.07 (-1.69%) 05/13/22 Maverix on track to achieve 2022 guidamce of 32K-35K attributable GEOs 03/16/22 Maverix Metals sees FY22 attributable GEOs 32,000-35,000 03/08/22 Maverix Metals acquires three royalties projects for $5M 02/28/22 Maverix Metals provides updates 2022 outlook MMX Maverix Metals $4.06 / -0.07 (-1.69%) 07/20/22 Stifel Maverix Metals price target lowered to C$8.25 from C$8.75 at Stifel 04/20/22 National Bank Maverix Metals price target raised to C$7 from C$6.75 at National Bank 04/20/22 Raymond James Maverix Metals price target raised to C$8.75 from C$8 at Raymond James 01/18/22 Raymond James Maverix Metals price target lowered to C$8 from C$8.50 at Raymond James MMX Maverix Metals $4.06 / -0.07 (-1.69%) 05/13/22 Maverix Metals reports Q1 adjusted EPS 4c, consensus 3c 03/16/22 Maverix Metals reports Q4 adjusted EPS 3c, consensus 3c
Earnings	Rapid Micro Biosystems reports Q2 EPS (31c) vs. ($20.01) last year » 07:02 08/12/22 08/12 07:02 08/12/22 07:02 RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 06/30/22 Rapid Micro confirms receipt of non-binding proposal from Kennedy Lewis 06/30/22 Kennedy Lewis proposes to buy Rapid Micro Biosystems for $5.00 per share in cash RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 10/14/21 Cowen Rapid Micro Biosystems coverage transferred at Cowen RPID Rapid Micro Biosystems $4.21 / -0.03 (-0.71%) 05/10/22 Rapid Micro Biosystems backs FY22 revenue view $27M-$32M, consensus $29.38M 05/10/22 Rapid Micro Biosystems reports Q1 EPS (35c), consensus (33c) 03/04/22 Rapid Micro Biosystems backs FY22 commercial revenue view $27M-$32M 03/04/22 Rapid Micro Biosystems reports Q4 EPS (35c), consensus (28c) 08:30 Today Rapid Micro Biosystems - RPID
Earnings	Honest Company reports Q2 EPS (11c), consensus (8c) » 07:02 08/12/22 08/12 07:02 08/12/22 07:02 HNST Honest Company $3.83 / +0.005 (+0.13%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options HNST Honest Company $3.83 / +0.005 (+0.13%) 07/19/22 Honest Company launches at Walmart to expand U.S. distribution 03/28/22 Honest Company partners with Fast 03/24/22 Honest Company drops 19% to $4.88 after Q4 results miss estimates HNST Honest Company $3.83 / +0.005 (+0.13%) 06/09/22 Loop Capital Loop Capital cuts Honest Company to Hold amid pressure reported in mass retail 06/09/22 Loop Capital Honest Company downgraded to Hold from Buy at Loop Capital 05/16/22 Loop Capital Honest Company price target lowered to $5 from $8 at Loop Capital 03/28/22 Citi Honest Company shares look 'awfully cheap' after selloff, says Citi HNST Honest Company $3.83 / +0.005 (+0.13%) 05/13/22 Honest Company still sees 2022 revenue growth view flat vs. 2021 05/13/22 Honest Company reports Q1 EPS (16c), consensus (15c) 03/24/22 Honest Company sees FY22 revenue flat, consensus $366.79M 03/24/22 Honest Company sees Q1 revenue down 15%, consensus $90.08M HNST Honest Company $3.83 / +0.005 (+0.13%) 06/09/22 What You Missed On Wall Street On Thursday 06/09/22 What You Missed On Wall Street This Morning 06/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/13/22 What You Missed On Wall Street On Friday 12:00 Today Honest Company - HNST HNST Honest Company $3.83 / +0.005 (+0.13%) 03/24/22 Honest Company options imply 7.1% move in share price post-earnings

Events

Earnings calls, analyst events, roadshows and more

HUMA
Today at 08:00

Humacyte - HUMA Conference Calls
CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
CASI
Today at 08:00

Casi Pharmaceuticals - CASI Conference Calls
GTEC
Today at 08:00

Greenland Technologies - GTEC Conference Calls
VERO
Today at 08:00

Venus Concept - VERO Conference Calls
EVK
Today at 08:00

Ever-Glory - EVK Conference Calls
CMMB
Today at 08:00

Chemomab Therapeutics - CMMB Conference Calls
Today at 08:30

Export Prices Y/Y: July 2022 Government Event
Today at 08:30

Import Prices M/M: July 2022 Government Event
Today at 08:30

Import Prices Y/Y: July 2022 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

Swatch Group price target lowered to CHF 360 from CHF 385 at Barclays

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access